Sign In
Buy VTVT
$32.94
-0.0600 (-0.182%)
At Close: Jun 03, 2026
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 02'nd Jun 2026
HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable
09:55am, Friday, 15'th May 2026
If you are looking for stocks that are well positioned to maintain their recent uptrend, vTv Therapeutics (VTVT) could be a great choice. It is one of the several stocks that passed through our "Recen
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 13'th May 2026
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13,
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 08'th May 2026
HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-i
vTv Therapeutics to Participate in Upcoming May Investor Conferences
08:00am, Thursday, 07'th May 2026
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-i
Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?
10:56am, Monday, 20'th Apr 2026
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Tuesday, 07'th Apr 2026
HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-
Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet
10:56am, Thursday, 02'nd Apr 2026
The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 31.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade
10:55am, Tuesday, 17'th Mar 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, t
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
08:00am, Monday, 16'th Mar 2026
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
04:01pm, Tuesday, 10'th Mar 2026
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance
VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst
05:11am, Saturday, 28'th Feb 2026
I think VTVT is a largely underfollowed T1D catalyst story, with Phase 3 CATT1 cadisegliatin topline expected in 2H2026. Cadisegliatin's Phase 2 SimpliciT-1 showed HbA1c improvement, fewer severe hypo
vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 61.2% in February
02:22am, Saturday, 28'th Feb 2026
vTv Therapeutics Inc. (NASDAQ: VTVT - Get Free Report) saw a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 50,829 shares, a growth
vTv Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Friday, 13'th Feb 2026
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-i
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
08:00am, Monday, 02'nd Feb 2026
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million u
